Drug Trial Radar · NCT06672393
A Study to Confirm Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis
Last checked: Nov 19, 2026Latest source record: Nov 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
375
Planned (sponsor's estimate)
Start
Nov 4, 2024
Primary completion
Oct 22, 2025
Study completion Jun 29, 2026
Sponsor
- Lead sponsor
- Hansoh BioMedical R&D CompanyIndustry
- Sponsor type
- Industry
- First posted
- Nov 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study has been designed to confirm the clinical efficacy and safety of HS-10374 in the treatment of moderate to severe plaque psoriasis.
Conditions
- Psoriasis
Interventions
HS-10374 6mg tabletsDrug
Specified dose of HS-10374 tablets administered orally QD on specified days
HS-10374-matched placebo tabletsDrug
Specified dose of HS-10374-matched placebo tablets administered orally QD on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients achieving PASI 75 response at Week 16Time frame: Baseline to Week 16
- Proportion of patients achieving sPGA 0/1 with at least 2 points improvement from baseline at Week 16Time frame: Baseline to Week 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huashan Hospital affiliated to Fudan University
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.